Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies

Drug Discovery Today

Volumn 12, Issue 7-8, 2007, Pages 336-342

  Dixit, Rakesh ^a   Boelsterli, Urs A ^b  

^a MEDIMMUNE   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NIMESULIDE; STAVUDINE; TGN 1412; TOLCAPONE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; DISEASE MODEL; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LIVER TOXICITY; NONHUMAN; PARKINSON DISEASE; PREDICTION; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE;

ANIMALS; ANTIBODIES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, ANIMAL;

EID: 33947595809     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.02.018     Document Type: Review

References (31)

1. Greaves P., et al. First dose of potential new medicines to humans: how animals help. Nat. Rev. Drug Discov. 3 (2004) 226-236
2. Olson H., et al. Concordance of the toxicity of pharmaceuticals in humans and animals. Regul. Toxicol. Pharmacol. 32 (2000) 56-67
3. Igrashi T., et al. Predictability of clinical adverse reactions of drugs by general pharmacology studies. J. Toxicol. Sci. 20 (1992) 77-92
4. Fletcher A.P. Drug safety tests and subsequent clinical experience. J. R. Soc. Med. 71 (1978) 693-696
5. Schein P.S., et al. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11 (1970) 3-40
6. Bhogal N., and Combs R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Altern. Lab. Anim. 34 (2006) 225-239
7. Wood A., and Darbyshire J. Injury to research volunteers - the clinical research nightmare. N. Engl. J. Med. 354 (2006) 1869-1871
8. Dorato M., and Vodicinik M. The toxicological assessment of pharmaceutical and biotechnology products. In: Hayes A. (Ed). Principles and Methods of Toxicology. 4th edn (2001), Taylor and Francis 243-283
9. Hickey, T.E. (1997) Animal care and use in toxicity testing. In Toxicological Testing and Evaluation (Vol. 2) (Comprehensive Toxicology) (Williams, P.D. and Hottendorf, G.H., eds), pp. 85-100, Elsevier
10. Boelsterli U.A. Animal models of human disease in drug safety assessment. J. Toxicol. Sci. 28 (2003) 109-121
11. Maritim A.C., et al. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17 (2003) 24-38
12. Sawant, S.P. et al. Mechanism of inhibited liver tissue repair in toxicant challenged type 2 diabetic rats. Toxicol. Appl. Pharmacol. (in press)
13. Wang, T. et al. Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit. Rev. Toxicol. (in press)
14. Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Saf. 16 (1997) 1-8
15. Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov. Today 11 (2006) 355-363
16. Zon L.I., and Peterson R. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4 (2005) 35-44
17. Smith W.L., and DeWitt D.L. Prostaglandin endoperoxidase H synthase-1 and -2. Adv. Immunol. 62 (1996) 167-215
18. Langenbach R., et al. Cyclooxygenase knockout mice. Biochem. Pharmacol. 58 (1999) 1237-1246
19. Mutlib A.E., et al. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol. Appl. Pharmacol. 168 (2000) 102-113
20. Mak D.H., and Ko K.M. Alterations in susceptibility to carbon tetrachloride toxicity and hepatic antioxidant/detoxification system in streptozotocin-induced short-term diabetic rats: effects of insulin and Schisandrin B treatment. Mol. Cell. Biochem. 175 (1997) 225-232
21. Wang T., et al. Enhanced hepatotoxicity and toxic outcome of thioacetamide in streptozotocin-induced diabetic rats. Toxicol. Appl. Pharmacol. 166 (2000) 92-100
22. Roth R.A., et al. Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents?. Toxicol. Appl. Pharmacol. 147 (1997) 300-311
23. Roth R.A., et al. Inflammation and drug idiosyncrasy - is there a connection?. J. Pharmacol. Exp. Ther. 307 (2003) 1-8
24. Buchweitz J.P., et al. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?. J. Pharmacol. Exp. Ther. 300 (2002) 460-467
25. Luyendyk J.P., et al. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307 (2003) 9-16
26. Lebovitz R.M., et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9782-9787
27. +/- mice. Free Radic. Biol. Med. 40 (2006) 420-429
28. Leitner H., and Day B. Mitochondrial antioxidant status and nucleoside reverse transcriptase inhibitor (NRTI) associated toxicity. Toxicol. Sci. 90 Suppl. (2006) 351
29. Williams M.D., et al. Increased oxidative damage is correlated to mitochondrial function in heterozygous manganese dismutase knockout mice. J. Biol. Chem. 273 (1998) 28510-28515
30. Huang T.T., et al. The use of transgenic and mutant mice to study oxygen free radical metabolism. Ann. N. Y. Acad. Sci. 893 (1999) 95-112
31. Van Remmen H., et al. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol. Genomics 16 (2003) 29-37